Drug Trial Radar · NCT04829773
Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects
Last checked: Nov 20, 2026Latest source record: Apr 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jan 3, 2019
Primary completion
Mar 29, 2019
Study completion Mar 29, 2019
Sponsor
- Lead sponsor
- Clementia Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study to evaluate the effect of food and the effect of swallowing capsule whole versus sprinkling on apple sauce on the pharmacokinetics (PK)/bioavailability of palovarotene, and evaluate the effect of palovarotene on the PK of the CYP3A4 substrate midazolam.
Conditions
- Fibrodysplasia Ossificans Progressiva
Interventions
PalovaroteneDrug
oral capsules
midazolamDrug
oral syrup
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum (peak) observed plasma drug concentrationTime frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13.
- Time to reach maximum (peak) (t max) observed plasma concentration following drug administrationTime frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
- Area under the plasma concentration time (AUC 0-last) curve from time zero to the last quantifiable time point, calculated by linear-log trapezoidal summationTime frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
- Area under the plasma concentration time curve from time zero to infinity (AUC 0-infinity)Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
- Apparent terminal disposition rate constant/terminal rate constant yzTime frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
- Apparent terminal elimination half-life (t1/2)Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
- Apparent volume of distribution after oral administration (Vd/F)Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
- Apparent total clearance of the drug from plasma after oral administration (cLF)Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
- Area under the plasma concentration time curve from time zero to 24 hours only for DDI cohortTime frame: Days 1, 2, 15, 16
- The last concentration before the next study drug administration at steady state for DDI cohortTime frame: Days 1, 2, 15, 16
- Maximum (peak) observed plasma drug concentration at steady state for DDI cohortTime frame: Days 1, 2, 15, 16
- Time to reach maximum (peak) observed plasma concentration following drug administration at steady state for DDI cohortTime frame: Days 1, 2, 15, 16
- Minimum observed plasma concentration at steady state, taken as the lowest plasma concentration during dosing interval for DDI cohortTime frame: Days 1, 2, 15, 16
- Accumulation ratio for DDI cohortTime frame: Days 1, 2, 15, 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cambridge Ipsen US
Cambridge, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.